Raymond Schinazi, an inventor and serial entrepreneur, has joined the UK start-up company reViral Ltd as a non-executive director. reViral was founded in 2011 around technology aimed at treating infection from the human respiratory syncytial virus (RSV). Professor Schinazi is a world leader in nucleoside chemistry and is responsible for advances in medicines to treat both HIV and hepatitis C viral infection. He is the founder of five biotechnology companies including Pharmasset Inc which was acquired by Gilead Sciences Inc in 2012. He is currently director of the Laboratory of Biochemical Pharmacology at Emory University in the US.
reViral announced the appointment on 15 April 2014.
Copyright 2014 Evernow Publishing Ltd